Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DEPTJ3D)

DME Name Steroid 5-alpha-reductase 2 (SRD5A2)
Synonyms Alpha-reductase steroid 2; 3-oxo-5-alpha-steroid 4-dehydrogenase 2; 5 alpha-SR2; S5AR 2; SR type 2; SRD5A2; Type II 5-alpha reductase
Gene Name SRD5A2
UniProt ID
S5A2_HUMAN
INTEDE ID
DME0218
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Gene ID
6716
EC Number EC: 1.3.1.22
Oxidoreductase
CH-CH donor oxidoreductase
NAD/NADP acceptor oxidoreductase
EC: 1.3.1.22
Lineage Species: Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Sequence
MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPARAAWFLQELPS
FAVPAGILARQPLSLFGPPGTVLLGLFCVHYFHRTFVYSLLNRGRPYPAILILRGTAFCT
GNGVLQGYYLIYCAEYPDGWYTDIRFSLGVFLFILGMGINIHSDYILRQLRKPGEISYRI
PQGGLFTYVSGANFLGEIIEWIGYALATWSLPALAFAFFSLCFLGLRAFHHHRFYLKMFE
DYPKSRKALIPFIF
Function This enzyme converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5- alpha-3-oxosteroids.
KEGG Pathway
Prostate cancer (hsa05215 )
Steroid hormone biosynthesis (hsa00140 )
Reactome Pathway
Androgen biosynthesis (R-HSA-193048 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DME
2 Approved Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone cypionate DMC1TEV N. A. N. A. Approved [5]
Testosterone enanthate DMB6871 N. A. N. A. Approved [5]

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DME
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 6.52E-02 1.61E-02 9.76E-02
Alopecia ED70 Skin from scalp 3.65E-01 -1.53E-01 -3.53E-01
Alzheimer's disease 8A20 Entorhinal cortex 9.64E-01 7.96E-03 4.87E-02
Ankylosing spondylitis FA92.0 Pheripheral blood 9.57E-01 1.27E-03 1.11E-02
Aortic stenosis BB70 Calcified aortic valve 9.54E-01 1.40E-01 3.52E-01
Apnea 7A40 Hyperplastic tonsil 1.30E-01 -2.64E-01 -2.44E+00
Arthropathy FA00-FA5Z Peripheral blood 2.58E-02 1.20E-01 9.35E-01
Asthma CA23 Nasal and bronchial airway 6.90E-01 6.11E-02 6.28E-02
Atopic dermatitis EA80 Skin 7.85E-01 -4.88E-02 -4.79E-01
Autism 6A02 Whole blood 8.21E-01 1.86E-02 8.93E-02
Autoimmune uveitis 9A96 Peripheral monocyte 5.57E-01 -1.76E-01 -1.81E+00
Autosomal dominant monocytopenia 4B04 Whole blood 2.52E-02 -2.20E-01 -1.45E+00
Bacterial infection of gingival 1C1H Gingival tissue 1.53E-05 1.06E-01 5.44E-01
Batten disease 5C56.1 Whole blood 8.96E-01 -6.32E-04 -6.95E-03
Behcet's disease 4A62 Peripheral blood 3.50E-01 -5.14E-02 -1.51E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 7.88E-01 -1.27E-02 -7.92E-02
Bladder cancer 2C94 Bladder tissue 3.02E-03 -3.49E-01 -1.89E+00
Breast cancer 2C60-2C6Z Breast tissue 4.51E-05 8.69E-02 3.21E-01
Cardioembolic stroke 8B11.20 Whole blood 1.55E-01 8.03E-02 4.37E-01
Cervical cancer 2C77 Cervical tissue 5.21E-01 -4.17E-03 -1.59E-02
Childhood onset rheumatic disease FA20.Z Peripheral blood 6.21E-01 -1.97E-02 -1.07E-01
Chronic hepatitis C 1E51.1 Whole blood 2.73E-01 1.34E-02 8.80E-02
Chronic obstructive pulmonary disease CA22 Lung tissue 5.41E-01 4.88E-02 2.04E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 8.35E-08 3.33E-01 6.13E-01
Chronic rhinosinusitis CA0A Sinus mucosa tissue 1.49E-01 -7.75E-01 -8.92E-01
Colon cancer 2B90 Colon tissue 2.70E-10 -1.73E-01 -6.97E-01
Coronary artery disease BA80-BA8Z Peripheral blood 3.44E-01 -4.43E-01 -6.99E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 9.54E-01 -3.72E-02 -3.63E-01
Endometriosis GA10 Endometrium tissue 5.61E-01 4.78E-02 1.63E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 3.30E-02 1.45E-01 1.00E+00
Familial hypercholesterolemia 5C80.00 Whole blood 1.19E-02 -1.04E-01 -4.40E-01
Gastric cancer 2B72 Gastric tissue 1.23E-01 -6.97E-01 -2.09E+00
Glioblastopma 2A00.00 Nervous tissue 1.60E-52 -3.14E-01 -1.18E+00
Glioma 2A00.0Y-2A00.0Z Brain stem tissue 4.43E-01 -1.67E-01 -9.44E-01
Glioma 2A00.0Y-2A00.0Z White matter tissue 1.16E-01 5.09E-02 1.73E-01
Head and neck cancer 2D42 Head and neck tissue 3.55E-14 -4.97E-01 -2.98E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 1.64E-01 -1.16E-01 -4.14E-01
Huntington's disease 8A01.10 Whole blood 5.75E-01 1.62E-02 5.90E-02
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 8.56E-01 7.76E-03 2.59E-02
Immunodeficiency 4A00-4A20 Peripheral blood 2.25E-01 8.27E-02 1.39E+00
Influenza 1E30 Whole blood 9.18E-03 5.28E-01 3.07E+00
Interstitial cystitis GC00.3 Bladder tissue 2.01E-01 -1.60E-01 -3.57E-01
Intracranial aneurysm 8B01.0 Intracranial artery 8.29E-01 7.49E-03 2.25E-02
Irritable bowel syndrome DD91.0 Rectal colon tissue 2.39E-01 7.11E-02 3.40E-01
Ischemic stroke 8B11 Peripheral blood 5.52E-02 6.05E-02 5.63E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 1.11E-03 1.47E-01 5.77E-01
Lateral sclerosis 8B60.4 Skin 2.02E-01 1.52E-01 9.19E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 5.20E-01 6.28E-02 3.39E-01
Liver cancer 2C12.0 Liver tissue 1.81E-24 -3.11E+00 -3.33E+00
Liver failure DB99.7-DB99.8 Liver tissue 8.82E-06 -1.91E+00 -2.62E+00
Lung cancer 2C25 Lung tissue 5.50E-06 -2.04E-01 -3.32E-01
Lupus erythematosus 4A40 Whole blood 9.02E-01 -3.98E-02 -9.83E-02
Major depressive disorder 6A70-6A7Z Hippocampus 4.02E-01 -6.86E-02 -5.30E-01
Major depressive disorder 6A70-6A7Z Whole blood 1.01E-02 4.10E-02 2.54E-01
Melanoma 2C30 Skin 4.10E-03 -3.26E-01 -4.42E-01
Multiple myeloma 2A83.1 Peripheral blood 3.64E-01 -5.25E-02 -2.51E-01
Multiple myeloma 2A83.1 Bone marrow 2.30E-01 -4.32E-02 -4.08E-01
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 4.85E-01 -5.25E-02 -3.48E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 5.85E-01 4.02E-03 2.47E-02
Myelofibrosis 2A20.2 Whole blood 4.58E-02 7.70E-02 4.86E-01
Myocardial infarction BA41-BA50 Peripheral blood 6.55E-01 4.81E-02 1.21E-01
Myopathy 8C70.6 Muscle tissue 1.11E-02 -2.72E-01 -1.46E+00
Neonatal sepsis KA60 Whole blood 5.11E-03 3.46E-02 1.69E-01
Neuroectodermal tumour 2A00.11 Brain stem tissue 2.82E-04 -5.31E-01 -1.96E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 4.90E-03 9.68E-01 1.39E+00
Obesity related type 2 diabetes 5A11 Omental adipose tissue 9.11E-01 -2.74E-03 -3.19E-02
Olive pollen allergy CA08.00 Peripheral blood 6.82E-01 7.06E-02 3.22E-01
Oral cancer 2B6E Oral tissue 4.22E-06 -3.03E-01 -1.21E+00
Osteoarthritis FA00-FA0Z Synovial tissue 1.59E-01 -2.76E-01 -8.20E-01
Osteoporosis FB83.1 Bone marrow 3.61E-02 3.17E-01 1.46E+00
Ovarian cancer 2C73 Ovarian tissue 7.16E-01 6.92E-02 6.13E-02
Pancreatic cancer 2C10 Pancreas 4.06E-01 -1.22E-01 -3.55E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 5.29E-01 5.82E-02 2.01E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 6.24E-01 4.15E-03 2.75E-02
Pituitary cancer 2D12 Pituitary tissue 2.03E-04 2.55E-01 1.57E+00
Pituitary gonadotrope tumour 2D12 Pituitary tissue 2.65E-02 2.64E-01 1.44E+00
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 2.58E-01 -6.45E-02 -5.50E-01
Polycythemia vera 2A20.4 Whole blood 6.17E-09 2.03E-01 1.29E+00
Pompe disease 5C51.3 Biceps muscle 1.25E-01 -1.75E-01 -8.41E-01
Preterm birth KA21.4Z Myometrium 5.83E-01 -7.76E-03 -3.95E-02
Prostate cancer 2C82 Prostate 1.43E-01 4.83E-01 5.62E-01
Psoriasis EA90 Skin 3.90E-05 -1.15E-01 -4.10E-01
Rectal cancer 2B92 Rectal colon tissue 2.06E-01 -1.23E-01 -5.52E-01
Renal cancer 2C90-2C91 Kidney 4.20E-03 -3.79E-01 -1.10E+00
Retinoblastoma 2D02.2 Uvea 3.34E-03 -1.51E-01 -1.38E+00
Rheumatoid arthritis FA20 Synovial tissue 1.91E-03 -6.27E-01 -2.00E+00
Rhinovirus infection CA42.1 Nasal epithelium tissue 6.76E-01 -5.33E-02 -7.23E-02
Schizophrenia 6A20 Prefrontal cortex 3.63E-01 -3.25E-02 -1.22E-01
Schizophrenia 6A20 Superior temporal cortex 4.36E-01 -2.96E-02 -3.00E-01
Scleroderma 4A42.Z Whole blood 1.81E-01 1.04E-01 8.16E-01
Seizure 8A60-8A6Z Whole blood 6.64E-02 -2.07E-01 -9.60E-01
Sensitive skin EK0Z Skin 8.24E-01 -7.25E-02 -3.31E-01
Sepsis with septic shock 1G41 Whole blood 8.76E-01 1.51E-03 5.86E-03
Shwachman-Diamond syndrome 3A70.0 Bone marrow 3.61E-01 -1.56E-01 -9.61E-01
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 1.59E-01 2.18E-01 5.46E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 1.21E-01 1.10E-01 8.25E-01
Sjogren's syndrome 4A43.2 Salivary gland tissue 3.63E-01 8.61E-02 1.02E+00
Skin cancer 2C30-2C3Z Skin 7.51E-02 -1.23E-01 -2.96E-01
Thrombocythemia 3B63 Whole blood 6.93E-04 6.51E-02 4.14E-01
Thrombocytopenia 3B64 Whole blood 6.09E-01 0.00E+00 0.00E+00
Thyroid cancer 2D10 Thyroid 2.77E-03 6.21E-02 3.37E-01
Tibial muscular dystrophy 8C75 Muscle tissue 1.09E-05 -3.17E-01 -1.65E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 5.05E-01 -1.10E-02 -1.43E-01
Type 2 diabetes 5A11 Liver tissue 3.81E-01 -2.08E-01 -5.17E-01
Ureter cancer 2C92 Urothelium 7.15E-01 3.75E-02 1.11E-01
Uterine cancer 2C78 Endometrium tissue 3.87E-02 3.95E-02 1.04E-01
Vitiligo ED63.0 Skin 3.60E-01 -8.92E-02 -2.49E-01
------------------------------------------------------------------------------------
⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name Steroid 5-alpha-reductase 2 (SRD5A2) DTT Info
DME DTT Type Successful
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Finasteride DMWV3TZ Baldness, male pattern Approved [1]
15 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid DMPHM23 Discovery agent N.A. Investigative [2]
(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid DMX5CY3 Discovery agent N.A. Investigative [2]
(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid DMOWGT3 Discovery agent N.A. Investigative [2]
2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ Discovery agent N.A. Investigative [3]
3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid DM75F1Q Discovery agent N.A. Investigative [2]
4,4'-dihydroxyoctafluoroazobenzene DM1ONBT Discovery agent N.A. Investigative [3]
4-(4-phenoxybenzoyl)benzoic acid DMOHB6U Discovery agent N.A. Investigative [2]
4-(4-phenoxybenzoyl)phenylacetic acid DMQ0JWZ Discovery agent N.A. Investigative [2]
4-[3-(benzyloxy)benzoyl]benzoic acid DMZU23D Discovery agent N.A. Investigative [2]
4-[4-(benzhydryloxy)benzoyl]benzoic acid DM8MVE9 Discovery agent N.A. Investigative [2]
4-[4-(benzoylamino)benzoyl]benzoic acid DM9VPFL Discovery agent N.A. Investigative [2]
4-[4-(benzylamino)benzoyl]benzoic acid DMQC5EH Discovery agent N.A. Investigative [2]
4-[4-benzyloxy)benzoyl]benzoic acid DMQ9IN4 Discovery agent N.A. Investigative [2]
GP515 DMRUIX3 Discovery agent N.A. Investigative [4]
{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid DMX53OY Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 15 Investigative Drug(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
3 Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
4 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29.
5 Molecular analysis of the SRD5A1 and SRD5A2 genes in patients with benign prostatic hyperplasia with regard to metabolic parameters and selected hormone levels. Int J Environ Res Public Health. 2017 Oct 30;14(11).